August 19, 2024

Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Immune-related (IR) colitis is a potentially life-threatening complication of checkpoint inhibitors. Its presentation often includes diarrhea, abdominal pain and rectal bleeding and the median time to onset is 6-10 weeks post initiation of immunotherapy.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Lukin et al. (Mon,) studied this question.

synapsesocial.com/papers/68e5bb33b6db6435875539ad https://doi.org/https://doi.org/10.1080/1750743x.2024.2386234

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma2022 · 557 citations
2Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management2018 · 274 citations
3Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).2023 · 8 citations
4Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial2019 · 781 citations
5Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib2020 · 1,213 citations

Preguntar a la IA

Me gusta

Guardar